VERTIS CV: Ertugliflozin’s proven benefits fall short of other SGLT2 inhibitorsSeptember 24, 2020Lipid DisordersDiabetesHeart Failure
Observational study again suggests lasting impact of COVID-19 on heartSeptember 21, 2020Heart FailureCOVID-19 Updates
Liberalized European sports cardiology guidelines break new groundSeptember 17, 2020CAD & AtherosclerosisPreventive CareHeart FailureArrhythmias & EPLipid Disorders
MIS-C cardiac evaluation requires more than EFSeptember 9, 2020Heart FailureCOVID-19 UpdatesPediatrics
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetesAugust 31, 2020Heart FailureDiabetes
EXPLORER trial hints at potential new drug option in obstructive hypertrophic cardiomyopathyAugust 30, 2020Heart Failure
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit solidifies class effectsAugust 30, 2020Heart FailureDiabetes
Pulmonary artery denervation eases PAH after endarterectomyAugust 20, 2020Heart FailureInterventional Cardiology & Surgery
Machine learning shows ability to predict diastolic dysfunction with ECGAugust 20, 2020Heart FailureArrhythmias & EP
Non-COVID-19 clinical trials grind to a halt during pandemicAugust 19, 2020Heart FailureCOVID-19 UpdatesAcute Coronary SyndromesArrhythmias & EPHypertensionImagingInterventional Cardiology & Surgery
